← Back
FeaturedOncology

Olomorasib (LY3537982)

Eli Lilly

Next-generation KRAS G12C inhibitor. SUNRAY-01 Phase 3 vs SOC in 1L KRAS G12C+ NSCLC. Best-in-class potential.

NSCLCKRAS G12C

Linked Studies

NCT05737706PrimaryTERMINATEDPHASE1

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Solid TumorAdvanced Solid TumorUpdated Apr 2025
Loading comments…

Also Known As

Development codes

LY3537982

Other names

olomorasib
Search all trials →Request coverage update